Assenagon Asset Management S.A. Atara Biotherapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$2.85 - $8.73 $15,002 - $45,954	-5,264 Reduced 0.87%	601,005 $2.27 Million
Q2 2022 Jul 27, 2022	SELL	$4.69 - $9.84 $578,825 - $1.21 Million	-123,417 Reduced 16.91%	606,269 $4.72 Million
Q1 2022 Apr 25, 2022	SELL	$8.44 - $16.89 $10.3 Million - $20.6 Million	-1,219,129 Reduced 62.56%	729,686 $6.78 Million
Q4 2021 Feb 01, 2022	BUY	$14.7 - $19.89 $6.45 Million - $8.73 Million	439,087 Added 29.08%	1,948,815 $30.7 Million
Q3 2021 Oct 19, 2021	BUY	$11.99 - $17.9 $153,519 - $229,191	12,804 Added 0.86%	1,509,728 $27 Million

Q2 2021 Jul 15, 2021	BUY	$12.89 - $16.58 $19.3 Million - $24.8 Million	1,496,924 New	1,496,924 $23.3 Million
Q3 2020 Oct 07, 2020	SELL	$11.92 - $15.87 $9.22 Million - $12.3 Million	-773,690 Closed	0 $0
Q2 2020 Jul 21, 2020	BUY	$7.53 - $14.93 $5.83 Million - $11.6 Million	773,690 New	773,690 $11.3 Million
Q1 2020 Apr 17, 2020	SELL	$5.69 - $17.78 $2.4 Million - $7.49 Million	-421,218 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$10.89 - $16.79 $4.59 Million - $7.07 Million	421,218 New	421,218 $6.94 Million
Q4 2018 Jan 23, 2019	SELL	$30.9 - $42.97 $12.8 Million - $17.9 Million	-415,520 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$35.05 - $43.5 $6.23 Million - $7.74 Million	177,852 Added 74.83%	415,520 $17.2 Million
Q2 2018 Jul 17, 2018	BUY	$35.15 - $51.45 $3.53 Million - $5.17 Million	100,432 Added 73.18%	237,668 $8.73 Million
Q1 2018 Apr 30, 2018	BUY	$18.0 - $48.35 $2.47 Million - $6.64 Million	137,236 New	137,236 $5.35 Million

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.